1. Home
  2. ADUS vs NTLA Comparison

ADUS vs NTLA Comparison

Compare ADUS & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADUS
  • NTLA
  • Stock Information
  • Founded
  • ADUS 1979
  • NTLA 2014
  • Country
  • ADUS United States
  • NTLA United States
  • Employees
  • ADUS N/A
  • NTLA N/A
  • Industry
  • ADUS Medical/Nursing Services
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • ADUS Health Care
  • NTLA Health Care
  • Exchange
  • ADUS Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • ADUS 2.1B
  • NTLA 794.5M
  • IPO Year
  • ADUS 2009
  • NTLA 2016
  • Fundamental
  • Price
  • ADUS $114.62
  • NTLA $9.63
  • Analyst Decision
  • ADUS Buy
  • NTLA Buy
  • Analyst Count
  • ADUS 10
  • NTLA 19
  • Target Price
  • ADUS $143.50
  • NTLA $35.11
  • AVG Volume (30 Days)
  • ADUS 166.2K
  • NTLA 5.0M
  • Earning Date
  • ADUS 08-04-2025
  • NTLA 08-07-2025
  • Dividend Yield
  • ADUS N/A
  • NTLA N/A
  • EPS Growth
  • ADUS 9.84
  • NTLA N/A
  • EPS
  • ADUS 4.42
  • NTLA N/A
  • Revenue
  • ADUS $1,211,561,000.00
  • NTLA $45,569,000.00
  • Revenue This Year
  • ADUS $23.16
  • NTLA N/A
  • Revenue Next Year
  • ADUS $5.77
  • NTLA N/A
  • P/E Ratio
  • ADUS $26.26
  • NTLA N/A
  • Revenue Growth
  • ADUS 11.38
  • NTLA N/A
  • 52 Week Low
  • ADUS $88.96
  • NTLA $5.90
  • 52 Week High
  • ADUS $136.72
  • NTLA $28.18
  • Technical
  • Relative Strength Index (RSI)
  • ADUS 57.98
  • NTLA 60.89
  • Support Level
  • ADUS $112.37
  • NTLA $8.88
  • Resistance Level
  • ADUS $115.16
  • NTLA $9.92
  • Average True Range (ATR)
  • ADUS 3.07
  • NTLA 0.64
  • MACD
  • ADUS -0.27
  • NTLA 0.12
  • Stochastic Oscillator
  • ADUS 63.86
  • NTLA 66.79

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: